![Joanna Smith](https://profiles-cardiff.imgix.net/attachments/3649?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Joanna Smith
- Available for postgraduate supervision
Teams and roles for Joanna Smith
Research Associate - Trial Manager
Overview
I have a track record of research in clinical trials, diagnostic development, genetics and microbiology and have built a reputation for excellence in clinical trial managment and methodology through the development and project management of multiple CTIMP and non-CTIMP national and international clinical trials in the solid tumour and haematological oncology and infection clinical settings. I am currently responsible for Trial Managmement of the RODEX and SAMADI clinical trials.
Publication
2023
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
2015
- Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
- Geldart, T. et al. 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67(4), pp. 599-602. (10.1016/j.eururo.2014.11.003)
2014
- Noble, S. et al. 2014. ALICAT: Anticoagulation length in cancer associated thrombosis - a mixed-methods feasibility study. Thrombosis Research 133(Supp 2), pp. S220-S220. (10.1016/S0049-3848(14)50032-1)
- Smith, J. D. et al. 2014. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study. Trials 15(1), article number: 122. (10.1186/1745-6215-15-122)
Articles
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
- Geldart, T. et al. 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67(4), pp. 599-602. (10.1016/j.eururo.2014.11.003)
- Noble, S. et al. 2014. ALICAT: Anticoagulation length in cancer associated thrombosis - a mixed-methods feasibility study. Thrombosis Research 133(Supp 2), pp. S220-S220. (10.1016/S0049-3848(14)50032-1)
- Smith, J. D. et al. 2014. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study. Trials 15(1), article number: 122. (10.1186/1745-6215-15-122)
Research
I originally trained as a PhD-level microbial geneticist at Warwick University, investigating protein secretion in the commercially important plant pathogen, Erwinia carotovora.
I expanded this specialism through three post-doctoral positions at Warwick and the University of Cambridge. This early research generated several peer reviewed publications in the areas of gene regulation in Erwinia, protein export in E.coli, and genetic diversity in Pseudomonas.
I transferred into industry in 2000, where I managed multiple national and international customer-led product development and research projects (including a SMART Cymru Award) using routine, and novel nucleic acid-based, lateral flow detection systems (Cytocell Ltd, and subsequently British Biocell International).
I moved to Cardiff University in 2008 when I joined the Wales Cancer Trials Unit (now part of the Centre for Trials Research; CTR Centre for Trials Research - Cardiff University). In this current role of have developed a specialised interest and research outputs in drug, surgical and medical device interventions in the clinical areas of haematological and solid tumour cancers, infections,and healthcare-related App development.
I was the study lead for two feasibility research projects:
- A neutropenic sepsis point of care (POCT) feasibility study involving collaboration with Velindre Patient Liaison Group and Cardiff & Vales University Health Board POCT Procurement team ADVANCE - Centre for Trials Research - Cardiff University
- BETR-C Digital: I-EAT App to support self-management of nutrition and improved treatment response in colorectal cancer patients. This research invovled a demographic survey, workshops with patients, carers and dieticians, and collaboration with a commercial start up App development company (Seastorm). BETRC-Digital - Centre for Trials Research - Cardiff University
And supported the development of FORE AI - The Future of Real Time Endoscopy Artificial Intelligence study aims to demonstrate the benefits of using AI in colonoscopy. FORE AI - Centre for Trials Research - Cardiff University
Other prior Cardiff University Clinical research collaborations and Trial Management responsibilities include two bladder cancer trials (SUCCINCT - Centre for Trials Research - Cardiff University, TOTEM - Centre for Trials Research - Cardiff University, a breast cancer trial FURVA - Centre for Trials Research - Cardiff University, and an observational study investigating prevalence of deep venous thrombosis in patients with advanced cancer (HIDDEN 2 - Centre for Trials Research - Cardiff University
I am currently affiliated to the CTR Infection, Inflammation and Immunity Divistion (Infection, Inflammation and Immunity Division - Centre for Trials Research - Cardiff University) and the Trial Manager for two infection-related trials in haematology and optometry respectively:
- RODEX: an international multicentre, randomized, open-label study of romiplostim plus dexamethasone vs dexamethasone in patients with newly diagnosed primary immune thrombocytopenia Clinical Trials register - Search for rodex.
- SAMADI: SAponins for MAcular DIsease: an exploratory randomised controlled trial (RCT) SAMADI - Centre for Trials Research - Cardiff University
Teaching
I do not have any academic teaching responsibilities at present. I have secondary education level tutoring and lab class demonstration experience through my external academic roles at the Universities of Warwick and Cambridge, and prior experience of industrial PhD student placement supervision through my industrial role at BBInternational.
Biography
Education and qualifications:
- 1997: PhD Biological Sciences, University of Warwick, UK
- 1993: MSc (Distinction) Molecular Genetics, Leicester University, UK
- 1992: BSc(Hons) Microbiology, Kent University, UK
Career overview:
- 2008 - present: Research Associate/Trial Manager, Centre for Clinical Trials (CTR), Cardiff University, UK
- 2020. Temporary Senior Trial Manager/Research Fellow, Centre for Trials Research (CTR), Cardiff University, UK
- 2019. Temporary Senior Trial Manager/Research Fellow, Centre for Trials Research (CTR), Cardiff University, UK
- 2013: Temporary Senior Trial Manager/Research Fellow, Wales Cancer Trials Unit (WCTU), Cardif University, UK
- 2003 - 2007: Project Leader, R&D, BBInternational Diagnostics, Cardiff, UK
- 2000 - 2003: Senior Research Scientist / Project Leader, Nucleic Acid Division, Cytocell Ltd, Coventry, UK
- 2000: Post Doctoral Reseach Assistant, Molecular Cell Biology, Warwick University, UK
- 1998 - 2000: Post Doctoral Reseach Assistant, Molecular Bacterial Ecology, Warwick University, UK
- 1997 - 1998: Post Doctoral Reseach Assistant, Department of Genetics, Cambridge University, UK
- 1990 - 1991: Industrial Trainee, Pfizer Central Research, Sandwich, Kent, UK
- 1990: Medical Laboratory Assistant, Rugby Hospital, Warwickshire, UK
- 1989: Medical Laboratory Assistant, Rugby Hospital, Warwickshire, UK
Professional memberships
- Member of the Trial Managers Network (TMN)
Academic positions
- 2000: Post Doctoral Reseach Assistant, Molecular Cell Biology, Warwick University, UK
- 1998 - 2000: Post Doctoral Reseach Assistant, Molecular Bacterial Ecology, Warwick University, UK
- 1997 - 2000: Post Doctoral Reseach Assistant, Department of Genetics, Cambridge University, UK
Supervisions
I am interested in supervising MSc, PhD and undergraduate students conducting clinical studies.
Contact Details
Research themes
Specialisms
- Clinical Trials
- Genetics
- Microbiology
- Project management
- Trial Management